← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
axitinib
L01EK01
Forms & Strengths
- Oral tablets: 1 mg
- Oral tablets: 2 mg
- Oral tablets: 3 mg
- Oral tablets: 5 mg
Adult Dosing
- Advanced renal cell carcinoma: 5 mg orally twice daily
- Titrate dose based on safety and tolerability (increase to 7 mg then 10 mg twice daily, or decrease to 3 mg then 2 mg twice daily)
- Administer approximately 12 hours apart with or without food
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of advanced renal cell carcinoma after failure of one prior systemic therapy
Mechanism of Action
- Selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3)
- Inhibits angiogenesis, tumor growth, and cancer cell progression
Adverse Reactions
- Hypertension
- Diarrhea
- Fatigue
- Decreased appetite
- Nausea
- Dysphonia
- Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)
- Weight decreased
- Vomiting
- Asthenia
- Constipation
- Arterial and venous thromboembolic events
- Hemorrhage
- Gastrointestinal perforation
- Hypothyroidism
- Proteinuria
Drug Interactions
- Strong CYP3A4/5 inhibitors (e.g., ketoconazole) increase axitinib exposure; reduce axitinib dose
- Strong CYP3A4/5 inducers (e.g., rifampin) decrease axitinib exposure; avoid coadministration or increase dose
- Moderate CYP3A4/5 inhibitors may increase exposure; monitor and adjust dose if needed
- Moderate CYP3A4/5 inducers may decrease exposure; avoid if possible
Curated Content: Needs Vetting Before Put to Clinical Use